 MELBOURNE, Australia, March 15, 2021 GLOBE NEWSWIRE -- Opthea Limited ASX:OPT; Nasdaq: OPT, a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, is pleased to announce that the first patient has been treated in the Phase 3 pivotal clinical program of the Companys first-in-class VEGF-CD trap inhibitor, OPT-302, in participants with treatment-naïve wet neovascular age-related macular degeneration AMD. The first patient was enrolled by Dr Allen Hu, MD, Cumberland Valley Retina Consultants, Hagerstown, Maryland, USA. 